SNK01
AssetAlso Troculeucel
Autologous natural killer (NK) cell therapy targeting neuroinflammation and abnormal protein aggregates.
- Stage
- Phase 1
- Modality
- Cell therapy
- Target
- Inflammation
- 1
- Indication
- 1
- Trial
- 1
- Developer
Indications
1Moderate Alzheimer disease
Phase 1, Recruiting, NCT06189963, clinicaltrials.gov, 7 Oct 2026
In the full profile
- Targets and what it contains1
- Owner and partners1
- Trials1
- Evidence for its targets1
- Aging relevance2
- Signals1
Every asset’s record: target, stage, trials and the evidence behind it.